Core Clinical Services

Executive Summary

Core Clinical Services, through its ImproWise platform, offers an integrated clinical trial management system that addresses the growing demand for digitalization in drug development. With over two decades of experience and a customer base of 200–500 employees, the company provides end-to-end solutions including CTMS, CDMS, EDC, eTMF, ePRO, and budget management. Its real-time analytics and regulatory compliance tools position it as a key enabler for sponsors, CROs, and trial sites seeking to accelerate timelines and reduce costs. As the clinical trial industry increasingly adopts cloud-based platforms, Core Clinical Services is well-poised to capture market share in India and expand globally. The company's competitive advantage lies in its comprehensive, all-in-one platform that simplifies complex workflows. However, it faces competition from larger players and must continuously innovate to maintain differentiation. With no disclosed funding or valuation, the company may be self-sustaining or exploring strategic investments. Given the market tailwinds from decentralized trials and regulatory harmonization, Core Clinical Services has moderate growth potential. Its ability to secure new partnerships, expand into emerging markets, or launch AI-driven features could serve as key catalysts.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a top-10 global CRO40% success
• Q4 2026Launch of AI-powered patient recruitment module60% success
• Q1 2027Expansion into Southeast Asian clinical trial market50% success